Kiltearn Partners LLP Makes New $35.74 Million Investment in CVS Health Corporation $CVS

by · The Markets Daily

Kiltearn Partners LLP purchased a new position in shares of CVS Health Corporation (NYSE:CVS – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 345,471 shares of the pharmacy operator’s stock, valued at approximately $35,739,000. CVS Health accounts for approximately 8.7% of Kiltearn Partners LLP’s investment portfolio, making the stock its 2nd biggest position.

A number of other large investors have also made changes to their positions in CVS. Sei Investments Co. boosted its holdings in CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after buying an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in CVS Health by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after buying an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in shares of CVS Health by 1.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after acquiring an additional 7,588 shares during the period. HUB Investment Partners LLC grew its holdings in shares of CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after acquiring an additional 3,011 shares during the period. Finally, Alliancebernstein L.P. increased its stake in CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on CVS shares. Cantor Fitzgerald boosted their target price on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Piper Sandler restated an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a research report on Monday, June 1st. Royal Bank Of Canada lifted their price target on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. Bank of America boosted their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Finally, Weiss Ratings raised shares of CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $107.17.

View Our Latest Report on CVS Health

CVS Health Price Performance

CVS stock opened at $93.01 on Friday. The stock’s 50 day moving average price is $102.02 and its 200 day moving average price is $88.86. The firm has a market cap of $118.96 billion, a P/E ratio of 24.61, a PEG ratio of 0.85 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68.

CVS Health (NYSE:CVS – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio is 70.37%.

About CVS Health

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Further Reading

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).